TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10500942

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (group COPA, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laryngeal mask (group LMA, n = 30)
Number of subjects: 60
Study: 8780536

Group type: EXPERIMENTAL
Intervention: p53 status in patients with recurrent disease
Number of subjects: 36

Group type: COMPARATOR
Intervention: p53 status in control group (without recurrent disease)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Comparison of detection techniques
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Overall p53 alteration
Number of subjects: 36
Study: 1600965

Group type: EXPERIMENTAL
Intervention: Milrinone bolus dose (50 micrograms kg‐1) followed by infusion at rates of 0.375, 0.5 or 0.75 microgram kg‐1 min‐1
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Milrinone infusion
Number of subjects: 99
Study: 6389233

Group type: COMPARATOR
Intervention: Continuous insulin infusion (CONT: 0.4 mU X kg‐1 X min‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pulsatile insulin infusion (PULS: 0.8 mU X kg‐1 X min‐1, 7.5 min of 15)
Number of subjects: 7
Study: 31918639

Group type: EXPERIMENTAL
Intervention: Growth mindset of personality intervention
Number of subjects: 60
Study: 31330804

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee plus isolated CAF (DECAF + CAF)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee plus isolated CAF plus soy oil (DECAF + CAF + SO)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee plus isolated CAF plus extra virgin coconut oil (DECAF + CAF + CO)
Number of subjects: 13
Study: 30126458

Group type: EXPERIMENTAL
Intervention: Vortioxetine plus celecoxib
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vortioxetine plus placebo
Number of subjects: 200
Study: 27084832

Group type: EXPERIMENTAL
Intervention: One (low intensity) IMT session for five months
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Three weekly IMT sessions (high intensity) for five months
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 15
Study: 25135542

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1% plus dexamethasone 0.1%
Number of subjects: 152

Group type: COMPARATOR
Intervention: Dexamethasone 0.1% alone
Number of subjects: 152
Study: 22295934

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Tacrolimus (Tac)
Number of subjects: 16
Study: 19326064

Group type: EXPERIMENTAL
Intervention: Subvastus approach for total knee replacement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Parapatellar approach for total knee replacement
Number of subjects: 100
Study: 17366918

Group type: EXPERIMENTAL
Intervention: Preoperative amino acid infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perioperative amino acid infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fructose infusion
Number of subjects: 0
Study: 16422256

Group type: EXPERIMENTAL
Intervention: Forced-air warming and fluid warming system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional cotton blanket
Number of subjects: 40
Study: 12002412

Group type: EXPERIMENTAL
Intervention: Octreotide (12 h infusion: bolus 0.75 microg/kg followed by 0.75 microg/kg/h)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9735391

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CT group) with low-dose oral UFT and continuous venous 5FU infusion.
Number of subjects: 42

Group type: COMPARATOR
Intervention: No chemotherapy (NCT group), n=28.
Number of subjects: 42
Study: 8903669

Group type: EXPERIMENTAL
Intervention: Perindopril and indapamide or matching placebos
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Perindopril alone or matching placebo
Number of subjects: 6000
Study: 2109573

Group type: EXPERIMENTAL
Intervention: Oral ofloxacin (single 400‐mg dose)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Intramuscular ceftriaxone (250‐mg dose)
Number of subjects: 89
Study: 6787417

Group type: EXPERIMENTAL
Intervention: Timolol (10 mg twice daily)
Number of subjects: 1884

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1884
Study: 31900274

Group type: EXPERIMENTAL
Intervention: Levofloxacin (once per day for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (once per day for 6 months)
Number of subjects: 0
Study: 31287556

Group type: EXPERIMENTAL
Intervention: Ringer's acetate with 200 mL mannitol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 40
Study: 27621150

Group type: EXPERIMENTAL
Intervention: PF-05190457 100 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: PF-05190457 150 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: PF-05190457 ≥50 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: PF-05190457
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 25605582

Group type: EXPERIMENTAL
Intervention: APBI using IMRT
Number of subjects: 520

Group type: COMPARATOR
Intervention: WBI
Number of subjects: 520
Study: 24481579

Group type: EXPERIMENTAL
Intervention: 50 mg iv dexketoprofen trometamol
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 1000 mg iv paracetamol
Number of subjects: 114

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 114
Study: 22162339

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) group program for RA fatigue
Number of subjects: 38
Study: 19074913

Group type: EXPERIMENTAL
Intervention: Prednisone 1-4 mg/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 16612837

Group type: EXPERIMENTAL
Intervention: Bivariate growth curve method for estimating trajectories
Number of subjects: 0
Study: 15893008

Group type: EXPERIMENTAL
Intervention: PORT (5040 cGy in 28 daily fractions)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: CPORT (PORT plus four cycles of cisplatin (60 mg/m2, day 1) and etoposide (120 mg/m2, days 1‐3) administered concurrently)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Age and gender matched controls
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Both treatment arms (PORT and CPORT)
Number of subjects: 488
Study: 12139537

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine 30 ml with 30 mg ketamine (Group K)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine 30 ml (Group P)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5% ropivacaine with 30 mg ketamine i.v. (Group C)
Number of subjects: 60
Study: 9801236

Group type: EXPERIMENTAL
Intervention: Danaparoid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 7630678

Group type: EXPERIMENTAL
Intervention: Stavudine (d4T) at doses ranging from 0.125 to 4 mg/kg/day in two divided doses
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Stavudine (d4T)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Prior zidovudine (ZDV) therapy
Number of subjects: 37
Study: 2756920

Group type: EXPERIMENTAL
Intervention: Vitamin A capsules
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 300
Study: 781610

Group type: EXPERIMENTAL
Intervention: K-P diet (diet eliminating artificial flavors, colors, and natural salicylates)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: K-P diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 15
Study: 31872894

Group type: EXPERIMENTAL
Intervention: SafeCare© (EBP implementation)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (services as usual)
Number of subjects: 102
Study: 31141807

Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 0
Study: 28601388

Group type: EXPERIMENTAL
Intervention: Rilotumumab with etoposide and carboplatin or cisplatin
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Ganitumab with etoposide and carboplatin or cisplatin
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo with etoposide and carboplatin or cisplatin
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Ganitumab
Number of subjects: 185
Study: 25968004

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (iCBT) program, completed over 10 weeks with six lessons.
Number of subjects: 4050

Group type: COMPARATOR
Intervention: Control group receiving the same iCBT after 12 months.
Number of subjects: 4050
Study: 23783784

Group type: EXPERIMENTAL
Intervention: PLBs under the guidance of the navigation system
Number of subjects: 52

Group type: COMPARATOR
Intervention: PLBs under the guidance navigation system with a low-dose (LD) protocol
Number of subjects: 52
Study: 21847802

Group type: EXPERIMENTAL
Intervention: Brief psychosocial/behavioral intervention for poststroke depression
Number of subjects: 0
Study: 19318446

Group type: EXPERIMENTAL
Intervention: 50 mg oral DHEA/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17341993

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combination therapy with valsartan and amlodipine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Valsartan or Amlodipine (after 8 weeks)
Number of subjects: 47
Study: 15194584

Group type: EXPERIMENTAL
Intervention: Ibuprofen (2400 mg/day)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo (in patients with knee swelling)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Ibuprofen (in patients with knee swelling)
Number of subjects: 201
Study: 11283391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Higher age cutoff for study entry
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Wider time window for study entry
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Greater stroke severity
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mean age of enrollees
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Multivariate models
Number of subjects: 90
Study: 9395946

Group type: EXPERIMENTAL
Intervention: BiPAP support
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ordinary oxygen mask treatment (control group)
Number of subjects: 20
Study: 8485268

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: COMPARATOR
Intervention: Tobramycin and Placebo
Number of subjects: 81
Study: 3481307

Group type: EXPERIMENTAL
Intervention: 40 mg furosemide plus 600 mg mofebutazone
Number of subjects: 10

Group type: COMPARATOR
Intervention: 40 mg furosemide
Number of subjects: 10
Study: 31098717

Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postsurgical supervised exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Opioids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurogenic pain medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Muscle relaxants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Decompression combined with instrumented fusion
Number of subjects: 0
Study: 29512813

Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block type I with 24 mL 0.375% ropivacaine per side
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 60
Study: 27559950

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise with behavioral approach (NSEB)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Prescribed physical activity (PPA)
Number of subjects: 194
Study: 24748353

Group type: EXPERIMENTAL
Intervention: Very early skin-to-skin contact (SSC)
Number of subjects: 0
Study: 23147455

Group type: COMPARATOR
Intervention: Placebo (n = 74)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 200 mg of zonisamide (n = 76)
Number of subjects: 225
Study: 20404311

Group type: EXPERIMENTAL
Intervention: COMT genotype (Met/Met, Met/Val, Val/Val) in white subjects
Number of subjects: 2858

Group type: EXPERIMENTAL
Intervention: COMT genotype (Met/Met, Met/Val, Val/Val) in black subjects
Number of subjects: 2858
Study: 18946293

Group type: EXPERIMENTAL
Intervention: Sugammadex (4.0 mg/kg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Neostigmine (70 microg/kg) plus glycopyrrolate (14 microg/kg)
Number of subjects: 74
Study: 15976804

Group type: EXPERIMENTAL
Intervention: HRV biofeedback
Number of subjects: 46

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 46
Study: 12364736

Group type: EXPERIMENTAL
Intervention: Aortic valve replacement
Number of subjects: 11
Study: 10426608

Group type: EXPERIMENTAL
Intervention: Leaflet group (received an information leaflet prior to attending the clinic)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 200
Study: 7589604

Group type: EXPERIMENTAL
Intervention: DTIC and interferon
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study: 2123561

Group type: EXPERIMENTAL
Intervention: Salsalate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enteric-coated aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0
Study: 7408650

Group type: EXPERIMENTAL
Intervention: Thyroxine (50-150 micrograms daily)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Iodine-containing salt (control)
Number of subjects: 213
Study: 31774566

Group type: EXPERIMENTAL
Intervention: F-652 (10, 30 or 45 μg/kg) administered on day-1 and 7
Number of subjects: 18
Study: 27225890

Group type: EXPERIMENTAL
Intervention: MP‐UKA
Number of subjects: 108

Group type: COMPARATOR
Intervention: CI‐UKA
Number of subjects: 108
Study: 26062182

Group type: EXPERIMENTAL
Intervention: Acupuncture to restore consciousness combined with hyperbaric oxygen treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Simple hyperbaric oxygen treatment
Number of subjects: 41
Study: 23546472

Group type: EXPERIMENTAL
Intervention: Group 1 (%LV with LGE <6%)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Group 2 (%LV with LGE ≥6%)
Number of subjects: 46
Study: 21336131

Group type: EXPERIMENTAL
Intervention: alanine‐glutamine dipeptide‐supplemented total parenteral nutrition
Number of subjects: 127

Group type: COMPARATOR
Intervention: control total parenteral nutrition
Number of subjects: 127
Study: 19370333

Group type: EXPERIMENTAL
Intervention: Surgery in patients < 1 year of age
Number of subjects: 124
Study: 17311603

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol laxative (17 g daily for 12 months)
Number of subjects: 311
Study: 15055890

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (n = 54)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Epidural (n = 59)
Number of subjects: 113
Study: 11673100

Group type: EXPERIMENTAL
Intervention: Clinical decision support systems (CDSS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental or randomized controlled clinical trials (RCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Field tests of CDSS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Evaluation literature
Number of subjects: 0
Study: 9627610

Group type: EXPERIMENTAL
Intervention: 2‐Octylcyanoacrylate (2‐OCA)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Nonabsorbable sutures/staples
Number of subjects: 83
Study: 7836506

Group type: EXPERIMENTAL
Intervention: GnRH agonist (buserelin, 500 micrograms/day s.c.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional HMG and HCG protocol
Number of subjects: 40
Study: 2970787

Group type: EXPERIMENTAL
Intervention: Autoperfusion catheter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard balloon catheter
Number of subjects: 0
Study: 26855561

Group type: EXPERIMENTAL
Intervention: Nemonoxacin with probenecid (1.5 g divided into three doses within 25 hours)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nemonoxacin with cimetidine (400 mg thrice daily for 7 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nemonoxacin alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nemonoxacin with probenecid or cimetidine
Number of subjects: 24
Study: 24417404

Group type: EXPERIMENTAL
Intervention: Coarse concentrated ambient particles (CAP) exposure for 2 hours
Number of subjects: 32
Study: 22124610

Group type: EXPERIMENTAL
Intervention: Resin composite sealants
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Glass-carbomer sealants
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer sealants with energy supplied
Number of subjects: 407

Group type: COMPARATOR
Intervention: High-viscosity glass-ionomer sealants without energy supplied
Number of subjects: 407
Study: 20236813

Group type: EXPERIMENTAL
Intervention: Adapted lactose-free formula fortified with S. boulardii (26mg/100ml), n=34
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard formula (control), n=36
Number of subjects: 70
Study: 18341671

Group type: EXPERIMENTAL
Intervention: ivabradine 10 mg b.i.d. for 4.5 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo for 4.5 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 15036788

Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11879270

Group type: EXPERIMENTAL
Intervention: Multimodal, multidisciplinary intervention involving rural healthcare providers and their healthcare system.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline data from the study.
Number of subjects: 0
Study: 9773769

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation-based stress reduction intervention (audiotaped instructions during light treatments)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control condition (light treatments alone with no taped instructions)
Number of subjects: 37
Study: 7522629

Group type: EXPERIMENTAL
Intervention: Chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) at doses of 10, 50, 100, 250, or 500 mg/m2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Chimeric anti-CD20 monoclonal antibody (IDEC-C2B8)
Number of subjects: 15
Study: 3122666

Group type: EXPERIMENTAL
Intervention: UFT 375 mg/m2/day + MMC 5 mg/m2 for 1‐2 weeks
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: UFT + ACNU 60 mg/m2/week for 2 weeks (with a 4-week interval)
Number of subjects: 104
Study: 31356262

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control
Number of subjects: 148
Study: 29438654

Group type: EXPERIMENTAL
Intervention: Positive 6-day fungal culture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative 6-day fungal culture
Number of subjects: 0
Study: 28444509

Group type: EXPERIMENTAL
Intervention: Educational intervention aimed at increasing adenoma detection rate (ADR)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Untrained group (control)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Trained group (intervention)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 263
Study: 26289955

Group type: EXPERIMENTAL
Intervention: Stride Management Assist (SMA®) System
Number of subjects: 50

Group type: COMPARATOR
Intervention: Functional Task Specific Training (FTST)
Number of subjects: 50
Study: 24570980

Group type: EXPERIMENTAL
Intervention: 5 × 5 mm dental implants with a novel nanostructured calcium-incorporated titanium surface
Number of subjects: 80

Group type: COMPARATOR
Intervention: at least 10 mm long implants in augmented bone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 5 × 5 mm dental implants
Number of subjects: 80

Group type: COMPARATOR
Intervention: at least 10 mm long implants
Number of subjects: 80
Study: 21420888

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 18155431

Group type: EXPERIMENTAL
Intervention: Providing an endoscopy report to patients after the procedure
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no report provided)
Number of subjects: 115
Study: 16940217

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg, 3 times daily for 16 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 14572169

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Atorvastatin (10 mg)
Number of subjects: 136
Study: 10982087

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9106924

Group type: EXPERIMENTAL
Intervention: Ialugen cream (hyaluronic acid)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 134
Study: 8472981

Group type: EXPERIMENTAL
Intervention: Epinephrine followed by polidocanol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Absolute alcohol
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 75
Study: 3705659

Group type: EXPERIMENTAL
Intervention: Telenzepine 1 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Telenzepine 2 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Telenzepine 3 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Telenzepine 5 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Telenzepine (all doses)
Number of subjects: 9
Study: 30094649

Group type: EXPERIMENTAL
Intervention: Xenograft (Bio‐Oss®)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alloplastic tricalcium phosphate (Sil‐Oss®)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no biomaterial)
Number of subjects: 6